Merck Research Laboratories CMO Eliav Barr at #JPM24 (Brian Benton Photography)
Eliav Barr defends Merck's LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data
Merck’s top medical exec said its recent bet on a VEGF bispecific antibody — one of the hottest areas in R&D — is not a form of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
